Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets?

Michelle M. Mielke; Constantine G. Lyketsos

doi:10.1007/s12017-010-8121-y

journal article Open Access Jun 23, 2010

Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets?

Michelle M. Mielke

Constantine G. Lyketsos

NeuroMolecular Medicine Vol. 12 No. 4 pp. 331-340 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/s12017-010-8121-y

Topics

No keywords indexed for this article. Browse by subject →

References

60

[1]

Ariga, T., McDonald, M. P., & Yu, R. K. (2008). Role of ganglioside metabolism in the pathogenesis of Alzheimer’s disease–a review. Journal of Lipid Research, 49, 1157–1175. 10.1194/jlr.r800007-jlr200

[2]

Bandaru, V. V., Troncoso, J., Wheeler, D., Pletnikova, O., Wang, J., Conant, K., et al. (2009). ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer’s but not normal brain. Neurobiology of Aging, 30, 591–599. 10.1016/j.neurobiolaging.2007.07.024

[3]

Berg, L., McKeel, D. W., Jr., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., et al. (1998). Clinicopathologic studies in cognitively healthy aging and Alzheimer’s disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Archives of Neurology, 55, 326–335. 10.1001/archneur.55.3.326

[4]

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261, 921–923. 10.1126/science.8346443

[5]

Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K., et al. (2004). Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. PNAS, 101, 2070–2075. 10.1073/pnas.0305799101

[6]

Cutler, R. G., Pedersen, W. A., Camandola, S., Rothstein, J. D., & Mattson, M. P. (2002). Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Annals of Neurology, 52, 448–457. 10.1002/ana.10312

[7]

DeMattos, R. B., Brendza, R. P., Heuser, J. E., Kierson, M., Cirrito, J. R., Fryer, J., et al. (2001). Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochemistry International, 39, 415–425. 10.1016/s0197-0186(01)00049-3

[8]

Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurology, 6, 734–746. 10.1016/s1474-4422(07)70178-3

[9]

Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., et al. (2005). Global prevalence of dementia: A Delphi consensus study. Lancet, 366, 2112–2117. 10.1016/s0140-6736(05)67889-0

[10]

Fillit, H. M. (2000). The pharmacoeconomics of Alzheimer’s disease. The American Journal of Managed Care, 6, S1139–S1144.

[11]

France-Lanord, V., Brugg, B., Michel, P. P., Agid, Y., & Ruberg, M. (1997). Mitochondrial free radical signal in ceramide-dependent apoptosis: A putative mechanism for neuronal death in Parkinson’s disease. Journal of Neurochemistry, 69, 1612–1621. 10.1046/j.1471-4159.1997.69041612.x

[12]

Frank, R., & Hargreaves, R. (2003). Clinical biomarkers in drug discovery and development. Nature Reviews, 2, 566–580.

[13]

Grimm, M. O., Grimm, H. S., Patzold, A. J., Zinser, E. G., Halonen, R., Duering, M., et al. (2005). Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nature Cell Biology, 7, 1118–1123. 10.1038/ncb1313

[14]

Growdon, J. H., Selkoe, D. J., Roses, A., et al. (1998). Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiology of Aging, 19, 109–116. 10.1016/s0197-4580(98)00022-0

[15]

Gulbins, E., & Kolesnick, R. (2003). Raft ceramide in molecular medicine. Oncogene, 22, 7070–7077. 10.1038/sj.onc.1207146

[16]

Han, X. (2005). Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s disease: Implication of the role of lipids in the pathogenesis of Alzheimer’s disease. Current Alzheimer Research, 2, 65–77. 10.2174/1567205052772786

[17]

Han, X., Cheng, H., Fryer, J. D., Fagan, A. M., & Holtzman, D. M. (2003a). Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. The Journal of Biological Chemistry, 278, 8043–8051. 10.1074/jbc.m212340200

[18]

Han, X., Fagan, A. M., Cheng, H., Morris, J. C., Xiong, C., & Holtzman, D. M. (2003b). Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Annals of Neurology, 54, 115–119. 10.1002/ana.10618

[19]

Han, X., Holtzman, D., McKeel, D. W., Jr., Kelley, J., & Morris, J. C. (2002). Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: Potential role in disease pathogenesis. Journal of Neurochemistry, 82, 809–818. 10.1046/j.1471-4159.2002.00997.x

[20]

Haughey, N. J., Cutler, R. G., Tamara, A., McArthur, J. C., Vargas, D. L., Pardo, C. A., et al. (2004). Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Annals of Neurology, 55, 257–267. 10.1002/ana.10828

[21]

He, X., Huang, Y., Li, B., Gong, C. X., & Schuchman, E. H. (2010). Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiology of Aging, 31(3), 398–408. 10.1016/j.neurobiolaging.2008.05.010

[22]

Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003). Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Archives of Neurology, 60, 1119–1122. 10.1001/archneur.60.8.1119

[23]

Hofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., et al. (1997). Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet, 349, 151–154. 10.1016/s0140-6736(96)09328-2

[24]

Holland, W. L., & Summers, S. A. (2008). Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism. Endocrine Reviews, 29, 381–402. 10.1210/er.2007-0025

[25]

Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., et al. (2008). Long-term effects of Abeta42 immunisation in Alzheimer’s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet, 372, 216–223. 10.1016/s0140-6736(08)61075-2

[26]

Huang, Y., Tanimukai, H., Liu, F., Iqbal, K., Grundke-Iqbal, I., & Gong, C. X. (2004). Elevation of the level and activity of acid ceramidase in Alzheimer’s disease brain. European Journal of Neuroscience, 20, 3489–3497. 10.1111/j.1460-9568.2004.03852.x

[27]

A New Clinical Scale for the Staging of Dementia

Charles P. Hughes, Leonard Berg, Warren Danziger et al.

British Journal of Psychiatry 1982 10.1192/bjp.140.6.566

[28]

Hur, J. Y., Welander, H., Behbahani, H., Aoki, M., Franberg, J., Winblad, B., et al. (2008). Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS Journal, 275, 1174–1187. 10.1111/j.1742-4658.2008.06278.x

[29]

Ichi, I., Nakahara, K., Miyashita, Y., Hidaka, A., Kutsukake, S., Inoue, K., et al. (2006). Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids, 41, 859–863. 10.1007/s11745-006-5041-6

[30]

Jana, A., & Pahan, K. (2004). Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer’s disease. Journal of Biological Chemistry, 279, 51451–51459. 10.1074/jbc.m404635200

[31]

Jorm, A. F., & Jolley, D. (1998). The incidence of dementia: A meta-analysis. Neurology, 51, 728–733. 10.1212/wnl.51.3.728

[32]

Kalvodova, L., Kahya, N., Schwille, P., Ehehalt, R., Verkade, P., Drechsel, D., et al. (2005). Lipids as modulators of proteolytic activity of BACE: Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. The Journal of Biological Chemistry, 280, 36815–36823. 10.1074/jbc.m504484200

[33]

Katsel, P., Li, C., & Haroutunian, V. (2007). Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochemical Research, 32, 845–856. 10.1007/s11064-007-9297-x

[34]

Koch, S., Donarski, N., Goetze, K., Kreckel, M., Stuerenburg, H. J., Buhmann, C., et al. (2001). Characterization of four lipoprotein classes in human cerebrospinal fluid. Journal of Lipid Research, 42, 1143–1151. 10.1016/s0022-2275(20)31605-9

[35]

Lee, J. T., Xu, J., Lee, J. M., Ku, G., Han, X., Yang, D. I., et al. (2004). Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. Journal of Cell Biology, 164, 123–131. 10.1083/jcb.200307017

[36]

Lomnitski, L., Oron, L., Sklan, D., & Michaelson, D. M. (1999). Distinct alterations in phospholipid metabolism in brains of apolipoprotein E-deficient mice. Journal of Neuroscience Research, 58, 586–592. 10.1002/(sici)1097-4547(19991115)58:4<586::aid-jnr11>3.0.co;2-7

[37]

Lyketsos, C. G., Szekely, C. A., Mielke, M. M., Rosenberg, P. B., & Zandi, P. P. (2008). Developing new treatments for Alzheimer’s disease: The who, what, when, and how of biomarker-guided therapies. International psychogeriatrics/IPA, 20, 871–889. 10.1017/s1041610208007382

[38]

Mahley, R. W. (1988). Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science, 240, 622–630. 10.1126/science.3283935

[39]

Marinier, A., Martel, A., Banville, J., Bachand, C., Remillard, R., Lapointe, P., et al. (1997). Sulfated galactocerebrosides as potential antiinflammatory agents. Journal of Medicinal Chemistry, 40, 3234–3247. 10.1021/jm9606960

[40]

Mattson, M. P., Cutler, R. G., & Jo, D. G. (2005). Alzheimer peptides perturb lipid-regulating enzymes. Nature Cell Biology, 7, 1045–1047. 10.1038/ncb1105-1045

[41]

Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., et al. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA, 302, 385–393. 10.1001/jama.2009.1064

[42]

Mayeux, R. (2003). Epidemiology of neurodegeneration. Annual Review of Neuroscience, 26, 81–104. 10.1146/annurev.neuro.26.043002.094919

[43]

Merched, A., Blain, H., Visvikis, S., Herbeth, B., Jeandel, C., & Siest, G. (1997). Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer’s disease. Journal of the Neurological Sciences, 145, 33–39. 10.1016/s0022-510x(96)00234-1

[44]

Mielke, M. M., Bandaru, V. V., Haughey, N. J., Rabins, P. V., Lyketsos, C. G., & Carlson, M. C. (2010a). Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiology of Aging, 31, 17–24. 10.1016/j.neurobiolaging.2008.03.011

[45]

Mielke, M. M., Bandaru, V. V. R., Haughey, N. J., Schech, S., Chu, M., Albert, M., et al. (2010b). Plasma ceramides are altered early in the course of Alzheimers disease. Alzheimer’s & Dementia, in press.

[46]

Mielke, M. M., & Lyketsos, C. G. (2006). Lipids and the pathogenesis of Alzheimer’s disease: Is there a link? International Review of Psychiatry, 18, 173–186. 10.1080/09540260600583007

[47]

Mielke, M. M., Rosenberg, P. B., Tschanz, J., Cook, L., Corcoran, C., Hayden, K. M., et al. (2007). Vascular factors predict rate of progression in Alzheimer disease. Neurology, 69, 1850–1858. 10.1212/01.wnl.0000279520.59792.fe

[48]

Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W., & Pitas, R. E. (1994). Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science, 264, 850–852. 10.1126/science.8171342

[49]

Nelson, J. C., Jiang, X. C., Tabas, I., Tall, A., & Shea, S. (2006). Plasma sphingomyelin and subclinical atherosclerosis: Findings from the multi-ethnic study of atherosclerosis. American Journal of Epidemiology, 163, 903–912. 10.1093/aje/kwj140

[50]

Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A., Hofman, A., & Breteler, M. M. (1999). Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 53, 1937–1942. 10.1212/wnl.53.9.1937

Showing 50 of 60 references

Cited By

119

GluN2B-containing NMDA receptors are upregulated in plasma membranes by the sphingosine-1-phosphate analog FTY720P

Suzanne Attiori Essis, Marie-Elaine Laurier-Laurin · 2015

Brain Research

Lipidomics of Alzheimer’s Disease

David Touboul, Mathieu Gaudin · 2014

Bioanalysis

Metrics

119

Citations

60

References

Details

Published: Jun 23, 2010
Vol/Issue: 12(4)
Pages: 331-340
License: View

Authors

M

Michelle M. Mielke

C

Constantine G. Lyketsos

Cite This Article

Michelle M. Mielke, Constantine G. Lyketsos (2010). Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets?. NeuroMolecular Medicine, 12(4), 331-340. https://doi.org/10.1007/s12017-010-8121-y

Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets?

You May Also Like